Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1. (Q44504681)

3 December 2017

title

Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1. (English)

1 reference

3 December 2017

Minkyoung Shin

1

1 reference

3 December 2017

Atsushi Mizokami

2

1 reference

3 December 2017

Jungim Kim

3

1 reference

3 December 2017

Mitsuo Ofude

4

1 reference

3 December 2017

Hiroyuki Konaka

5

1 reference

3 December 2017

Yoshifumi Kadono

6

1 reference

3 December 2017

Yasuhide Kitagawa

7

1 reference

3 December 2017

Sotaro Miwa

8

1 reference

3 December 2017

Misako Kumaki

9

1 reference

3 December 2017

Evan T Keller

10

1 reference

3 December 2017

Mikio Namiki

11

1 reference

3 December 2017

language of work or name

1 reference

26 March 2013

1 reference

3 December 2017

1 reference

3 December 2017

volume

73

1 reference

3 December 2017

issue

11

1 reference

3 December 2017

page(s)

1159-1170

1 reference

3 December 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Osteoblasts in prostate cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Lymphadenectomy in minimally invasive urologic oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Stromal factors involved in prostate carcinoma metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

SPARC (osteonectin/BM-40).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

A prototypic matricellular protein in the tumor microenvironment--where there's SPARC, there's fire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

SPARC in cancer biology: its role in cancer progression and potential for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

SPARC and tumor growth: where the seed meets the soil?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

The tail of integrins, talin, and kindlins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

SPARC-null mice exhibit accelerated cutaneous wound closure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

SPARC: a matricellular regulator of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

The role of SPARC in the TRAMP model of prostate carcinogenesis and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Bone matrix osteonectin limits prostate cancer cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Role of the Akt pathway in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Integrins in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Can cancer be reversed by engineering the tumor microenvironment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

The role of the microenvironment in tumor growth and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Targeting the PI3K/AKT pathway for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Retracted: SPARC Overexpression Inhibits Cell Proliferation in Neuroblastoma and Is Partly Mediated by Tumor Suppressor Protein PTEN and AKT

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

β1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22664

21 January 2018

Identifiers

DOI

10.1002/PROS.22664

1 reference

release_wmmumvcrkvdfta6xhvr4uwh2t4

3 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wmmumvcrkvdfta6xhvr4uwh2t4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference